Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation

This study has been terminated.
(The clinical use of Campath for transplant patients was temporarily suspended.)
Sponsor:
Collaborators:
Bayer
Gruessner, Rainer, MD
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier:
NCT00177138
First received: September 13, 2005
Last updated: February 5, 2013
Last verified: February 2013
  Purpose

This is a single center, prospective, open-label, randomized trial at the University of Minnesota Medical Center,Fairview.

Primary objectives are to determine if rejection episodes and loss rates, graft survival, level of renal graft function, and patient survival rates with a Campath/MMF-based (Group 1) immunosuppressive protocol are lower than, or equal to, our protocol using thymoglobulin, tacrolimus, and MMF (Group 2).

This study will investigate the first protocol that is both steroid-free and calcineurin inhibitor-free in pancreas after kidney transplant recipients.


Condition Intervention Phase
Diabetes Mellitus
Drug: Tacrolimus
Drug: Alemtuzumab
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation

Resource links provided by NLM:


Further study details as provided by University of Minnesota - Clinical and Translational Science Institute:

Primary Outcome Measures:
  • Time-to-event analysis will be used to analyze categorical end points that include graft failure, patient survival, biopsy documented rejection episode and non-compliance. [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • The continuous outcome variable, weekly or bi-weekly serum creatinine levels, will be analyzed using a two-way repeated-measures analysis of variance. [ Time Frame: 2 years ]

Enrollment: 9
Study Start Date: July 2004
Study Completion Date: November 2006
Arms Assigned Interventions
Active Comparator: Group 2
Tacrolimus/MMF/TMG
Drug: Tacrolimus
Starting POD #1 0.06 mg/kg/day in 2 divided doses;
Experimental: Group 1
Campath/MMF/TMG
Drug: Alemtuzumab
30 mg IV intra-op and POD #12; then 30 mg IV >monthly for 1 year (only if ALC>200 mm, up to a total of 10 doses in year)

Detailed Description:

Secondary objectives of the study are:

  1. Compare the side effects of the immunosuppressive medications between both groups. This will include anaphylactic reactions, GI side-effects, bone marrow suppression, renal dysfunction, hypertension, hyperglycemic effects, and effects on lipid profile.
  2. Compare the incidence of infections between both groups.

Comparison parameters are:

  1. Pancreas and kidney graft failure
  2. Patient death
  3. Clinical and biopsy documented rejection episodes
  4. Patient dropout (non-compliance with the study protocol)
  5. Kidney function as assessed by creatinine clearance or biopsy
  6. Need to change immunosuppression regimen
  7. Quality-adjusted Life Years
  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Previous kidney transplant from a living or deceased donor and a deceased- donor pancreas transplant.
  2. Recipient age 18-60 years
  3. Donor age 10-59 years
  4. Females of childbearing potential should have a negative pregnancy test, and agree to practice birth control for the duration of the study.
  5. Enteric or bladder drained pancreas transplant.

    -

Exclusion Criteria:

  1. Use of an investigational drug in the last 1-year.
  2. Positive T or B cell crossmatch.
  3. WBC<3000 at enrollment
  4. Platelet count <50,000 at enrollment
  5. History of malignancy (exclusive of minor skin cancers)
  6. Inability to give informed consent
  7. Systemic infections
  8. Major active or chronic infections, including documented HIV infection (by any licensed ELISA and confirmation by Western Blot).
  9. Serology negative for EBV pre-transplant.
  10. No other previous organ transplants other than pancreas and/or kidney. -
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00177138

Locations
United States, Minnesota
University of Minnesota-Fairview
Minneapolis, Minnesota, United States, 55414
Sponsors and Collaborators
University of Minnesota - Clinical and Translational Science Institute
Bayer
Gruessner, Rainer, MD
Investigators
Principal Investigator: Rainer W Gruessner, M.D. University of Minnesota - Clinical and Translational Science Institute
  More Information

No publications provided

Responsible Party: University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier: NCT00177138     History of Changes
Other Study ID Numbers: 0308M51264, Berlex Study No. 107.G0001
Study First Received: September 13, 2005
Last Updated: February 5, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of Minnesota - Clinical and Translational Science Institute:
Campath Study
Pancreas After Kidney Transplantation
Alemtuzumab

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pancrelipase
Tacrolimus
Alemtuzumab
Gastrointestinal Agents
Therapeutic Uses
Pharmacologic Actions
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents

ClinicalTrials.gov processed this record on August 21, 2014